|
16 Apr 2021 |
Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
|
|
16 Apr 2021 |
Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs
|
|
16 Apr 2021 |
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
|
|
16 Apr 2021 |
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
|
|
15 Apr 2021 |
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
|
|
15 Apr 2021 |
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
|
|
15 Apr 2021 |
Merck to Discontinue Development of MK-7110 for COVID-19
|
|
15 Apr 2021 |
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
|
|
15 Apr 2021 |
Genentech’s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)
|
|
15 Apr 2021 |
New protein degradation centre to lead drug discovery revolution
|
|
15 Apr 2021 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
|
|
15 Apr 2021 |
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
|
|
14 Apr 2021 |
Agenus Doses First Cancer Patient with iNKT Cell Therapy
|
|
14 Apr 2021 |
Aquavit to Introduce A New Botulinum Toxin (DTX-021)
|
|
14 Apr 2021 |
TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Like Receptor Agonists
|
|
14 Apr 2021 |
TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer
|
|
14 Apr 2021 |
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
|
|
13 Apr 2021 |
Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy
|
|
13 Apr 2021 |
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
|
|
13 Apr 2021 |
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
|
